vs
Side-by-side financial comparison of CROWN HOLDINGS, INC. (CCK) and Zoetis (ZTS). Click either name above to swap in a different company.
CROWN HOLDINGS, INC. is the larger business by last-quarter revenue ($3.3B vs $2.4B, roughly 1.4× Zoetis). Zoetis runs the higher net margin — 25.3% vs 6.3%, a 18.9% gap on every dollar of revenue. On growth, CROWN HOLDINGS, INC. posted the faster year-over-year revenue change (12.9% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $-129.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs 3.5%).
Danish Crown is an internationally oriented Danish food company with butchery operations, processing and sales of primarily pork and beef. Through a number of subsidiaries, the group is widely represented within the food industry with various food products. The CEO is Niels Duedahl and the headquarters are located in Randers.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
CCK vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.3B | $2.4B |
| Net Profit | $206.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 11.2% | 31.9% |
| Net Margin | 6.3% | 25.3% |
| Revenue YoY | 12.9% | 3.0% |
| Net Profit YoY | -9.3% | 3.8% |
| EPS (diluted) | $175.00 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.3B | — | ||
| Q4 25 | $3.1B | $2.4B | ||
| Q3 25 | $3.2B | $2.4B | ||
| Q2 25 | $3.1B | $2.5B | ||
| Q1 25 | $2.9B | $2.2B | ||
| Q4 24 | $2.9B | $2.3B | ||
| Q3 24 | $3.1B | $2.4B | ||
| Q2 24 | $3.0B | $2.4B |
| Q1 26 | $206.0M | — | ||
| Q4 25 | $150.0M | $603.0M | ||
| Q3 25 | $214.0M | $721.0M | ||
| Q2 25 | $181.0M | $718.0M | ||
| Q1 25 | $193.0M | $631.0M | ||
| Q4 24 | $358.0M | $581.0M | ||
| Q3 24 | $-175.0M | $682.0M | ||
| Q2 24 | $174.0M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 11.2% | — | ||
| Q4 25 | 12.0% | 31.9% | ||
| Q3 25 | 13.2% | 37.0% | ||
| Q2 25 | 12.4% | 36.7% | ||
| Q1 25 | 12.6% | 36.5% | ||
| Q4 24 | 12.1% | 31.6% | ||
| Q3 24 | 14.4% | 36.6% | ||
| Q2 24 | 12.5% | 33.0% |
| Q1 26 | 6.3% | — | ||
| Q4 25 | 4.8% | 25.3% | ||
| Q3 25 | 6.7% | 30.0% | ||
| Q2 25 | 5.7% | 29.2% | ||
| Q1 25 | 6.7% | 28.4% | ||
| Q4 24 | 12.3% | 25.1% | ||
| Q3 24 | -5.7% | 28.6% | ||
| Q2 24 | 5.7% | 26.4% |
| Q1 26 | $175.00 | — | ||
| Q4 25 | $1.32 | $1.37 | ||
| Q3 25 | $1.85 | $1.63 | ||
| Q2 25 | $1.56 | $1.61 | ||
| Q1 25 | $1.65 | $1.41 | ||
| Q4 24 | $3.01 | $1.29 | ||
| Q3 24 | $-1.47 | $1.50 | ||
| Q2 24 | $1.45 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $584.0M | — |
| Total DebtLower is stronger | $53.0M | — |
| Stockholders' EquityBook value | $3.4B | $3.3B |
| Total Assets | $14.3B | $15.5B |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $584.0M | — | ||
| Q4 25 | $764.0M | — | ||
| Q3 25 | $1.2B | $2.1B | ||
| Q2 25 | $936.0M | $1.4B | ||
| Q1 25 | $779.0M | $1.7B | ||
| Q4 24 | $918.0M | $2.0B | ||
| Q3 24 | $1.7B | $1.7B | ||
| Q2 24 | $1.4B | $1.6B |
| Q1 26 | $53.0M | — | ||
| Q4 25 | $5.9B | — | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $6.2B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $7.4B | — | ||
| Q2 24 | $7.3B | — |
| Q1 26 | $3.4B | — | ||
| Q4 25 | $3.0B | $3.3B | ||
| Q3 25 | $3.0B | $5.4B | ||
| Q2 25 | $2.9B | $5.0B | ||
| Q1 25 | $2.7B | $4.7B | ||
| Q4 24 | $2.8B | $4.8B | ||
| Q3 24 | $2.5B | $5.2B | ||
| Q2 24 | $2.5B | $5.0B |
| Q1 26 | $14.3B | — | ||
| Q4 25 | $14.3B | $15.5B | ||
| Q3 25 | $14.6B | $15.2B | ||
| Q2 25 | $14.5B | $14.5B | ||
| Q1 25 | $13.8B | $14.1B | ||
| Q4 24 | $13.8B | $14.2B | ||
| Q3 24 | $15.1B | $14.4B | ||
| Q2 24 | $14.9B | $14.2B |
| Q1 26 | 0.02× | — | ||
| Q4 25 | 1.96× | — | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 2.18× | — | ||
| Q1 25 | 2.31× | — | ||
| Q4 24 | 2.23× | — | ||
| Q3 24 | 2.93× | — | ||
| Q2 24 | 2.92× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $893.0M |
| Free Cash FlowOCF − Capex | $-129.0M | $732.0M |
| FCF MarginFCF / Revenue | -4.0% | 30.7% |
| Capex IntensityCapex / Revenue | 2.7% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $487.0M | $893.0M | ||
| Q3 25 | $580.0M | $938.0M | ||
| Q2 25 | $449.0M | $486.0M | ||
| Q1 25 | $14.0M | $587.0M | ||
| Q4 24 | $295.0M | $905.0M | ||
| Q3 24 | $554.0M | $951.0M | ||
| Q2 24 | $445.0M | $502.0M |
| Q1 26 | $-129.0M | — | ||
| Q4 25 | $255.0M | $732.0M | ||
| Q3 25 | $488.0M | $805.0M | ||
| Q2 25 | $393.0M | $308.0M | ||
| Q1 25 | $-19.0M | $438.0M | ||
| Q4 24 | $146.0M | $689.0M | ||
| Q3 24 | $478.0M | $784.0M | ||
| Q2 24 | $361.0M | $370.0M |
| Q1 26 | -4.0% | — | ||
| Q4 25 | 8.2% | 30.7% | ||
| Q3 25 | 15.2% | 33.5% | ||
| Q2 25 | 12.5% | 12.5% | ||
| Q1 25 | -0.7% | 19.7% | ||
| Q4 24 | 5.0% | 29.7% | ||
| Q3 24 | 15.5% | 32.8% | ||
| Q2 24 | 11.9% | 15.7% |
| Q1 26 | 2.7% | — | ||
| Q4 25 | 7.4% | 6.7% | ||
| Q3 25 | 2.9% | 5.5% | ||
| Q2 25 | 1.8% | 7.2% | ||
| Q1 25 | 1.1% | 6.7% | ||
| Q4 24 | 5.1% | 9.3% | ||
| Q3 24 | 2.5% | 7.0% | ||
| Q2 24 | 2.8% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 3.25× | 1.48× | ||
| Q3 25 | 2.71× | 1.30× | ||
| Q2 25 | 2.48× | 0.68× | ||
| Q1 25 | 0.07× | 0.93× | ||
| Q4 24 | 0.82× | 1.56× | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | 2.56× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCK
| Americas Beverage | $1.5B | 47% |
| European Beverage | $588.0M | 18% |
| Transit Packaging | $496.0M | 15% |
| Other | $342.0M | 10% |
| Asia Pacific | $303.0M | 9% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
